· Trials · Trials Desk
751 participants, 72 weeks, maximum tolerated doses: −20.2% on tirzepatide versus −13.7% on semaglutide. The endpoints, the confidence intervals, and the caveats.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.